Comparison of half and full doses of an MF59-adjuvanted cell culture-derived A/H1N1v vaccine in Japanese children
The substantial pandemic (A/H1N1v) influenza disease burden in children highlights the need for effective vaccination. We report the results of modern cell culture technology, lower doses of antigen, and different doses of MF59® adjuvant (Novartis Vaccines, Marburg, Germany), on the immunogenicity and safety profile in a healthy Japanese pediatric population.
A total of 123 children from 6 months to 19 years of age were randomly assigned in a 1:1 ratio to receive, at 21-day intervals, two doses of either 3.75 μg antigen with 50% of the standard MF59 dose (group A) or 7.5 μg antigen and 100% standard MF59 dose (group B). Antibody levels were measured by hemagglutinin inhibition (HI) and microneutralization assays on day 1 and on days 22 and 43 (3 weeks after the first and second vaccinations, respectively). Solicited adverse events were reported for 7 days after each injection and spontaneous events were reported throughout the study period.
At 3 weeks after the first vaccination, seroprotective HI antibodies (titers ≥40) were observed in 56% and 78% of subjects from groups A and B, respectively; 100% in both groups exhibited HI titers ≥40 after the second dose. The reactogenicity profile was acceptable, with local and systemic reactions described as mainly mild to moderate in severity. Five serious adverse events were reported, but none related to the study vaccine.
One dose of cell culture-derived A/H1N1v vaccine containing 7.5 μ g antigen with the full MF59 adjuvant dose was immunogenic and well tolerated in healthy Japanese children, meeting all three European Union Committee for Medicinal Products for Human Use (EU CHMP) licensure criteria. Two doses of 3.75 μg antigen with 50% of the standard MF59 dose fulfilled these licensure criteria.
Keywordscell culture vaccine children A/H1N1v influenza MF59 adjuvant
- 1.World Health Organization. DG statement following the meeting of the Emergency Committee. Available at: www.who.int/csr/disease/swineflu/4th_meeting_ihr/en/index.html. Accessed June 11, 2009.
- 2.Centers for Disease Control and Prevention. Swine influenza A (H1N1) infection in two children—Southern California, March–April 2009. MMWR Morb Mortal Wkly Rep. 2009;58:400–402.Google Scholar
- 3.World Health Organization. Pandemic H1N1 2009-Update 86 Geneva. Available at: www.who.int/csr/don/2010_01_29/en/index.html. Accessed January 29, 2010.
- 4.Kamigaki T, Oshitani H. Epidemiological characteristics and low case fatality rate of pandemic (H1N1) 2009 in Japan. PLoS Curr Influenza. 2009:RRN1139.Google Scholar
- 5.Centers for Disease Control and Prevention. Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine. MMWR Morb Mortal Wkly Rep. 2009;58:521–524.Google Scholar
- 9.US Food and Drug Administration, Center for Biological Evaluation and Research. Guidance for industry: clinical data needed to support the licensure of pandemic influenza vaccines. Available at: www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm074786.htm. Accessed June 1, 2010.
- 14.Vajo Z, Tamas F, Sinka L, Jankovics I. Safety and immunogenicity of a 2009 pandemic influenza A H1N1 vaccine when administered alone or simultaneously with the seasonal influenza vaccine for the 2009-10 influenza season: a multicentre, randomised controlled trial. Lancet. 2010;375:49–55.CrossRefPubMedGoogle Scholar
- 22.Worlth Health Organization. Global alert and response: WHO recommendations on pandemic (H1N1) 2009 vaccines. Available at: www.who.int/csr/disease/swineflu/notes/h1n1_vaccine_20090713/en/index.html. Accessed June 1, 2009.
- 23.Centers for Disease Control and Prevention. Deaths related to 2009 pandemic influenza A (H1N1) among American Indian/Alaska Natives - 12 states, 2009. MMWR Morb Mortal Wkly Rep. 2009;58:1341–1344.Google Scholar
- 29.CHMP. Guideline on Influenza Vaccines Pepared from Viruses with the Potential to Cause a Pandemic and Intended for Use Outside of the Core Dossier Context EMEA/CPMP/VWP/263499/2006, 24 January 2007. Available at: www.ema.europa.eu/pdfs/human/vwp/26349906enfin.pdf. Accessed June 1, 2010.
- 30.CHMP. Guideline on Dossier Structure and Content for Pandemic Influenza Vaccine Marketing Authorisation Application (Revision, EMEA/CPMP/VEG/4717/2002-Rev1). 18 December 2008. Available at: www.ema.europa.eu/pdfs/human/vwp/471703enfin.pdf. Accessed June 1, 2010.
- 34.Center for Disease Control and Prevention. Update on influenza A (H1N1) 2009 monovalent vaccines. MMWR Morb Mortal Wkly Rep. 2009;58:1100–1101.Google Scholar